Another SA article on ATHX today interviewing the CEO. Must be 5 or 6 in the last few weeks. Cytori should take a cue from this, particularly the interview. Maybe CC would be willing to be interviewed by a SA contributor such as yourself.
I'd like to interview CC but the timing is not right because I'd have to be focused on shareholder frustration due to the timing of expectations that have repeatedly not been met. At this point a SA article can't really help, We are beyond that. Cytori need to deliver on promises of a substantive partnership and EU No Option CMI (a claim which I believe has been expanded to cover many additional vascular related indications). When these goals come to fruition, an interview about the ramifications would be more helpful.
Remember when Cytori cancelled the last few of weeks of the Seaside financing because they were pressured by some shareholders to show some confidence in a pending partnership deal? I was against it and in the end all it did was reduce credibility further when a partnership to clear up balance sheet concerns could not be delivered in time. Credibility will only be regained with results at this point.
Titan-- I as you have done quite well with ATHX. I recently picked up more at 1.05 but wished I had doubled my purchase. This one has room to run. Perfect example of a team well managed, and another one treading water not knowing which way is land. Cytori needs help. It's management lacks direction and energy.
I haven't followed NBS closely but took a look after you asked. I'd stay focused on ATHX and CYTX and drop NBS based on my limited review. I note this:
"PCT has provided services to over 100 clients in its 12-year history, and is the only contract manufacturing organization to have worked with a client’s product (Dendreon, Inc.’s Provenge) through all of the phases of clinical trials and ultimately to FDA approval. PCT offers its clients and NeoStem cell processing and development capabilities on both the East and West Coasts of the U.S. PCT is built on a strong foundation of services that cater to the industry as a whole, reducing our reliance on the success of our own varied technology platforms in that we still have the opportunity to capture growing revenues from industry growth. Furthermore, PCT’s manufacturing revenues would increase significantly should a client progress through Phase I, II, and III trials and into commercialization where larger numbers of cells are needed."
The Dendreon model (autologous with significant processing) will eventually be obsolete, IMHO. Too expensive and it will bankrupt our already burdened healthcare system if it were to become widely used.